Business
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange.
About this update from Evofem Biosciences, Inc.
[{"type":"text","content":"\n\n\n\nEvofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEvofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange\nPR Newswire\nSAN DIEGO, Aug. 22, 2023\n\n\n\nSAN DIEGO, Aug. 22, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI) relating to a possible merger with a publicly-traded entity which, if consummated, could result in Evofem being listed on a national stock exchange (the \"Transaction\"). The Company is still in negotiations, has not executed a definitive agreement, and neither party is under any obligation to enter into or continue negotiations regarding a definitive agreement relating to the Transaction.\n\n \n \n \n \n \n \n\n \n\"We believe re-establishing a national listing for our stock could be in the best interest of our shareholders and essential to the long-term success of the Company. This could remove certain barriers for institutional investors and analysts who are prohibited from investing in and covering over-the counter stocks and is a significant step toward overcoming some of the challenges Evofem has faced over the past year,\" said Saundra Pelletier, CEO of Evofem Biosciences. \"Beyond the national exchange listing, this possible merger could offer funding, strategic support and operational expertise that we believe could accelerate Evofem's mission and could generate additional revenue opportunities for the combined company.\"\nAbout Evofem BiosciencesEvofem Biosciences, Inc., is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phe...